Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.

R Sumareva, G Ukrainsky, L Kiremidjian-Schumacher, M Roy, H I Wishe, A D Steinfeld, J S Cooper
{"title":"Effect of combined adoptive immunotherapy and radiotherapy on tumor growth.","authors":"R Sumareva,&nbsp;G Ukrainsky,&nbsp;L Kiremidjian-Schumacher,&nbsp;M Roy,&nbsp;H I Wishe,&nbsp;A D Steinfeld,&nbsp;J S Cooper","doi":"10.1002/(SICI)1520-6823(1999)7:1<22::AID-ROI3>3.0.CO;2-6","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced squamous cell carcinomas of the head and neck are difficult to control despite optimal surgery, radiotherapy and/or chemotherapy, and the tumors are usually not immunogenic. Because of the anatomic accessibility of the tumors, local adoptive immunotherapy of these tumors is feasible and may interact with radiotherapy to retard tumor growth. It is hypothesized that antigens released from tumor cells injured by radiation may stimulate, in the presence of interleukin-2, an enhanced immunocytodestruction of live tumor cells by adoptively transferred lymphokine activated killer cells and recruited tumor cytotoxic cells. DBA/2 mice were injected subcutaneously with 5 x 10(5) syngeneic squamous cell carcinoma cells in the thigh and the resulting tumors were treated for two weeks with daily peritumoral injections of interleukin-2 (1,000 International Units) or saline, four radiation treatments of 625 cGy each, and four peritumoral injections of 10(7) lymphokine activated killer cells. The results suggested that radiotherapy combined with peritumoral injection of lymphokine activated killer cells and interleukin-2 resulted in a significant reduction (P < 0.01) of tumor size whereas radiation alone, at the same dose, failed to produce a significant effect. Such results may have direct clinical application in enhancing the response of tumors to radiotherapy and in reducing the incidence of tumor recurrence.</p>","PeriodicalId":20894,"journal":{"name":"Radiation oncology investigations","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/(SICI)1520-6823(1999)7:1<22::AID-ROI3>3.0.CO;2-6","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation oncology investigations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/(SICI)1520-6823(1999)7:1<22::AID-ROI3>3.0.CO;2-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 12

Abstract

Advanced squamous cell carcinomas of the head and neck are difficult to control despite optimal surgery, radiotherapy and/or chemotherapy, and the tumors are usually not immunogenic. Because of the anatomic accessibility of the tumors, local adoptive immunotherapy of these tumors is feasible and may interact with radiotherapy to retard tumor growth. It is hypothesized that antigens released from tumor cells injured by radiation may stimulate, in the presence of interleukin-2, an enhanced immunocytodestruction of live tumor cells by adoptively transferred lymphokine activated killer cells and recruited tumor cytotoxic cells. DBA/2 mice were injected subcutaneously with 5 x 10(5) syngeneic squamous cell carcinoma cells in the thigh and the resulting tumors were treated for two weeks with daily peritumoral injections of interleukin-2 (1,000 International Units) or saline, four radiation treatments of 625 cGy each, and four peritumoral injections of 10(7) lymphokine activated killer cells. The results suggested that radiotherapy combined with peritumoral injection of lymphokine activated killer cells and interleukin-2 resulted in a significant reduction (P < 0.01) of tumor size whereas radiation alone, at the same dose, failed to produce a significant effect. Such results may have direct clinical application in enhancing the response of tumors to radiotherapy and in reducing the incidence of tumor recurrence.

过继免疫治疗与放疗联合治疗对肿瘤生长的影响。
头颈部的晚期鳞状细胞癌很难控制,尽管最佳的手术,放疗和/或化疗,肿瘤通常不是免疫原性的。由于肿瘤的解剖可及性,局部过继免疫治疗这些肿瘤是可行的,并可能与放疗相互作用,以延缓肿瘤的生长。据推测,受辐射损伤的肿瘤细胞释放的抗原可能在白细胞介素-2存在的情况下,通过过继转移淋巴因子激活的杀伤细胞和募集肿瘤细胞毒性细胞,增强了对活肿瘤细胞的免疫细胞破坏。在DBA/2小鼠大腿皮下注射5 × 10(5)个同基因鳞状细胞癌细胞,形成肿瘤后,每天在瘤周注射白介素-2(1000国际单位)或生理盐水,4次每次625 cGy的放射治疗,4次瘤周注射10(7)个淋巴细胞激活的杀伤细胞。结果表明,放疗联合瘤周注射淋巴因子活化的杀伤细胞和白细胞介素-2可显著减小肿瘤大小(P < 0.01),而在相同剂量下单独放疗未产生显著效果。这些结果可能在提高肿瘤对放疗的反应和降低肿瘤复发率方面具有直接的临床应用价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信